查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1456913

凝血分析仪市场－2024年至2029年预测

Coagulation Analyzer Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

凝血分析仪市场预计将以 5.91% 的复合年增长率成长，从 2022 年的 34.41 亿美元增至 2029 年的 51.44 亿美元。

凝血分析仪市场是指用于分析凝血过程的医疗设备的全球市场，凝血过程是人体形成血栓的自然能力。这些医疗设备主要用于诊断和监测与凝血障碍相关的疾病，例如血栓症、血友病和冯维勒布兰德病。凝血分析仪利用光学、机械和电化学方法等多种技术来测量血液样本中的凝血参数。测量的参数包括凝血时间、凝血酶原时间、活化部份凝血活酵素时间和国际标准化比率。

凝血疾病的盛行率不断增加，以及用于诊断目的的凝血分析仪的需求不断增长，是推动对这些解决方案的需求的关键因素。此外，自动凝血分析仪的采用和先进凝血检测的市场开拓也有助于市场成长。凝血分析仪市场竞争激烈，大大小小的公司都在满足广泛的需求。这些公司提供各种凝血分析仪和相关产品，包括试剂、品管品和消耗品。此外，先进凝血分析新兴市场的开拓和自动化凝血分析仪的采用预计将推动凝血分析仪市场的成长。与传统手动方法相比，自动凝血分析仪具有更高的准确性、效率和速度。此外，先进凝血检测的发展将使临床医生能够准确有效地诊断和监测凝血障碍。

市场驱动力

  • 凝血障碍盛行率的上升正在推动市场成长。

血栓症、血友病和血管性血友病等凝血疾病的盛行率不断增加，是凝血分析仪市场的主要驱动力。根据世界血友病联合会的数据，全世界约有 40 万人患有血友病，冯维乐布兰氏症影响着全球约 1% 的人口。这些疾病的日益普及预计将推动对用于诊断目的的凝血分析仪的需求。

  • 老年人口增加推动市场扩张

人口老化也是凝血分析仪市场的主要驱动因素之一。随着年龄的增长，发生凝血障碍的风险会增加。根据美国统计，到2050年，全球65岁以上人口预计将达到15亿，高于2019年的7.03亿，比2015年增加2%。人口老化的加剧预计将在预测期内推动对凝血分析仪的需求。

  • 测试显示凝血分析仪的需求预计将大幅成长

由于出血性疾病盛行率的增加、老年人口的增加以及对照护现场的需求的增加，用于血小板功能检测的凝血分析仪的全球市场显示出显着的成长前景。血小板功能测试用于评估血小板形成血栓的能力，并已成为识别和治疗各种出血性疾病的重要诊断工具。由于先进血小板功能检测设备的发展、医疗保健支出的增加以及疾病早期诊断需求的增加，预计该市场将大幅增长。此外，在研究活动和临床试验中使用血小板功能测试预计将推动市场成长。

北美在全球凝血分析仪市场中占有很大份额。

从地区来看，凝血分析仪市场分为北美、南美、欧洲、中东和非洲以及亚太地区。由于凝血障碍盛行率不断增加、医疗保健成本不断上升以及对先进凝血测试的需求不断增长，预计北美凝血分析仪市场将在预测期内显着增长。由于其领先的市场参与企业、成熟的医疗基础设施和积极的政府倡议，美国预计将成为该地区的主要市场。

主要进展

  • 2021 年 7 月，Sysmex Europe 为欧洲、中东和非洲地区选定国家的大中型医院和商业实验室推出了两款新型自动化凝血分析仪 CN-3500 和 CN-6500，现已上市。这些设备使用化学冷光酵素免疫分析法测定 (CLEIA) 在一台设备中测量各种血栓症和止血相关参数。这些设备能够测量凝血的分子标记物，并记录血栓性疾病的早期诊断和适当治疗。 CN-3500和CN-6500采用整合方法进行止血测试，比使用多种不同测量原理的仪器的传统方法更加复杂和耗时，提高了生产率、可靠性，并旨在提高可操作性和可维护性。
  • 2021年10月，领先的医疗设备Trivitron Healthcare与Diagon-Vanguard Diagnostics India合作，针对印度诊断领域推出了一系列新的凝血分析仪产品。 COAG 系列由匈牙利 Diagon 製造的自动、半自动和 POC 系统组成，可降低手术期间出血的风险，确定止血治疗和抗凝血剂的有效性，并改善患者管理。这些凝血分析仪以其高通量和基于试剂的测试能力而闻名，从而提高了实验室效率和周转时间。

目录

第一章 简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章凝血分析仪市场：依类型

  • 介绍
  • 半自动凝血分析仪
  • 全自动凝血分析仪
  • 其他的

第六章 凝血分析仪市场：通过测试

  • 介绍
  • 纤维蛋白原测试
  • D-二聚体测试
  • 血小板功能测试
  • 其他的

第七章凝血分析仪市场：依技术分类

  • 介绍
  • 光学技术
  • 机械技术
  • 电化学技术
  • 其他的

第 8 章 凝血分析仪市场：依最终使用者分类

  • 介绍
  • 医院
  • 诊断中心
  • 其他的

第九章凝血分析仪市场：按地区

  • 介绍
  • 北美洲
  • 南美洲
  • 欧洲
  • 中东/非洲
  • 亚太地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • Roche
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthcare GmbH
  • Abbott
  • Beckman Coulter Diagnostics
  • Helena Laboratories Corporation
  • Meril Life Sciences Pvt. Ltd.
  • Trivitron Healthcare
  • Symex
简介目录
Product Code: KSI061614994

The coagulation analyzer market is projected to grow at a CAGR of 5.91% to reach US$5.144 billion in 2029 from US$3.441 billion in 2022.

The coagulation analyzer market refers to the global market for medical devices used to analyse the coagulation process, which is the body's natural ability to form blood clots. These devices are primarily used to diagnose and monitor conditions related to blood clotting disorders such as thrombophilia, hemophilia, and von Willebrand disease. Coagulation analyzers utilize various technologies, such as optical, mechanical, and electrochemical methods, to measure the coagulation parameters of a blood sample. The measured parameters include clotting time, prothrombin time, activated partial thromboplastin time, and international normalized ratio, among others.

The increasing prevalence of blood clotting disorders and the rising demand for coagulation analyzers for diagnostic purposes are the key factors driving the need for these solutions. Moreover, adopting automated coagulation analyzers and developing advanced coagulation assays are also contributing to the market growth. The coagulation analyzer market is highly competitive, with several large and small players catering to the wide demand. These players offer various coagulation analyzers and related products, such as reagents, controls, and consumables. Further, the development of advanced coagulation assays and the adoption of automated coagulation analyzers are expected to drive the growth of the coagulation analyzer market. Automated coagulation analyzers offer advantages over traditional manual methods, such as increased accuracy, efficiency, and speed. Moreover, developing advanced coagulation assays enables clinicians to accurately and efficiently diagnose and monitor blood clotting disorders.

Market Drivers

  • The rising prevalence of blood clotting disorders is propelling the market growth.

The increasing prevalence of blood clotting disorders such as thrombophilia, hemophilia, and von Willebrand disease is a major driver of the coagulation analyzer market. According to the World Federation of Hemophilia, approximately 400,000 people worldwide have hemophilia, while von Willebrand disease affects around 1% of the global population. The rising incidence of these disorders is expected to drive the demand for coagulation analyzers for diagnostic purposes.

  • The growing geriatric population has propelled the market expansion.

The aging population is another major driver of the coagulation analyzer market. As people age, their risk of developing blood clotting disorders increases. According to the United Nations, the global population aged 65 years and above is expected to reach 1.5 billion by 2050, up from 703 million in 2019, and the same source states, that the population aged 65years and above accounted for 10% of the global population, which signified a 2% increase over 2015's percent share. This increase in the aging population is expected to drive the demand for coagulation analyzers during the projected period.

  • Based on the test, the coagulation analyzer demand is expected to show significant growth

The global coagulation analyzer market for platelet function tests reveals significant growth prospects due to the increasing prevalence of bleeding disorders, the rising geriatric population, and the growing demand for point-of-care testing. Platelet function tests are used to evaluate the ability of platelets to form blood clots, making them an important diagnostic tool in identifying and managing various bleeding disorders. The market is expected to grow significantly due to the development of advanced platelet function testing devices, increasing healthcare expenditure, and the growing demand for early disease diagnosis. Using platelet function tests in research activities and clinical trials will also drive market growth.

North America accounted for a significant share of the global coagulation analyzer market.

Based on geography, the coagulation analyzer market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The North American coagulation analyzer market is expected to grow significantly during the projected period due to the increasing prevalence of coagulation disorders, rising healthcare expenditure, and growing demand for advanced coagulation testing. The United States is expected to be a significant market in this region due to major market players, well-established healthcare infrastructure, and favourable government initiatives.

Key Developments:

  • In July 2021, Sysmex Europe launched two new automated blood coagulation analyzers, the CN-3500 and CN-6500, for medium- to large-scale hospitals and commercial labs in select countries in the EMEA region. These devices use the chemiluminescence enzyme immunoassay (CLEIA) methodology to measure various thrombosis and hemostasis-related parameters with a single device. They can measure molecular markers for blood coagulation, offering early-stage diagnosis and appropriate treatment for thrombotic diseases. The CN-3500 and CN-6500 aim to improve productivity, reliability, operability, and serviceability for healthcare settings by using an integrated approach to hemostasis testing that is less complex and time-consuming than the traditional method, which uses multiple instruments with different measurement principles.
  • In October 2021, Trivitron Healthcare, a leading firm in medical devices, partnered with Diagon-Vanguard Diagnostics India to introduce a new series of Coagulation Analyzer products for the Indian diagnostics sector. The COAG Line comprises automated, semi-automated, and POC systems produced by Diagon Hungary to decrease bleeding risks during surgeries, determine the efficacy of hemostatic therapies and anticoagulant medicines, and improve patient management. These coagulation analyzers are widely known for their ability to test with high throughput and reagents, thereby increasing laboratory efficiency and turnaround time.

Segmentation:

By Type

  • Semi-Auto Coagulation Analyzer
  • Fully-Auto Coagulation Analyzer
  • Other

By Test

  • Fibrinogen Testing
  • D-Dimer Testing
  • Platelet Function Test
  • Others

By Technology

  • Optical Technology
  • Mechanical Technology
  • Electrochemical Technology
  • Others

By End User

  • Hospitals
  • Diagnostic Centers
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. COAGULATION ANALYZER MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Semi-Auto Coagulation Analyzer
    • 5.2.1. Market Trends and Opportunities
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness Insight
  • 5.3. Full-Auto Coagulation Analyzer
    • 5.3.1. Market Trends and Opportunities
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness Insight
  • 5.4. Other
    • 5.4.1. Market Trends and Opportunities
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness Insight

6. COAGULATION ANALYZER MARKET BY TEST

  • 6.1. Introduction
  • 6.2. Fibrinogen Testing
    • 6.2.1. Market Trends and Opportunities
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness Insight
  • 6.3. D-Dimer Testing
    • 6.3.1. Market Trends and Opportunities
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness Insight
  • 6.4. Platelet Function Tests
    • 6.4.1. Market Trends and Opportunities
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness Insight
  • 6.5. Others
    • 6.5.1. Market Trends and Opportunities
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness Insight

7. COAGULATION ANALYZER MARKET BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Optical Technology
    • 7.2.1. Market Trends and Opportunities
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness Insight
  • 7.3. Mechanical Technology
    • 7.3.1. Market Trends and Opportunities
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness Insight
  • 7.4. Electrochemical Technology
    • 7.4.1. Market Trends and Opportunities
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness Insight
  • 7.5. Others
    • 7.5.1. Market Trends and Opportunities
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness Insight

8. COAGULATION ANALYZER MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospital
    • 8.2.1. Market Trends and Opportunities
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness Insight
  • 8.3. Diagnostic Centers
    • 8.3.1. Market Trends and Opportunities
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness Insight
  • 8.4. Others
    • 8.4.1. Market Trends and Opportunities
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness Insight

9. COAGULATION ANALYZER MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Type
    • 9.2.2. By Test
    • 9.2.3. By Technology
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Trends and Opportunities
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Trends and Opportunities
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Trends and Opportunities
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Type
    • 9.3.2. By Test
    • 9.3.3. By Technology
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Trends and Opportunities
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Trends and Opportunities
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Trends and Opportunities
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Type
    • 9.4.2. By Test
    • 9.4.3. By Technology
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Trends and Opportunities
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Trends and Opportunities
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. United Kingdom
        • 9.4.5.3.1. Market Trends and Opportunities
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Spain
        • 9.4.5.4.1. Market Trends and Opportunities
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Others
        • 9.4.5.5.1. Market Trends and Opportunities
        • 9.4.5.5.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Type
    • 9.5.2. By Test
    • 9.5.3. By Technology
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Trends and Opportunities
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. Israel
        • 9.5.5.2.1. Market Trends and Opportunities
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Trends and Opportunities
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Type
    • 9.6.2. By Test
    • 9.6.3. By Technology
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Trends and Opportunities
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. Japan
        • 9.6.5.2.1. Market Trends and Opportunities
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Trends and Opportunities
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Trends and Opportunities
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Indonesia
        • 9.6.5.5.1. Market Trends and Opportunities
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Taiwan
        • 9.6.5.6.1. Market Trends and Opportunities
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Others
        • 9.6.5.7.1. Market Trends and Opportunities
        • 9.6.5.7.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Roche
  • 11.2. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 11.3. Siemens Healthcare GmbH
  • 11.4. Abbott
  • 11.5. Beckman Coulter Diagnostics
  • 11.6. Helena Laboratories Corporation
  • 11.7. Meril Life Sciences Pvt. Ltd.
  • 11.8. Trivitron Healthcare
  • 11.9. Symex